Overall verdict
Buy
6.5/10
1-year performance
+16.61%
Score breakdown
Up 16.6% over 1 year, 77% of the 52-week range.
Strongest: Profitability 10.0/10. Weakest: Valuation 4.7/10.
26 analysts, target +0.0% vs the price.
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics ;
cell line and cell culture media development services ; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish ; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites ; lab filtration, separation, and purification ; lab-scale protein purification and analytical tools ;
reagents, membranes, and services for diagnostic and assay development ; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers ; bioanalytical measurement systems ; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization ; genome sample preparation ; microscopes ;
protein consumables ; filtration products ; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
Sector
Health Care
Industry
Life Sciences Tools and Services
Primary listing
Nyse
United States
CEO
Rainer Blair
Founded
1969
Employees
60 000
Revenue / employee
409 467 USD
Next earnings
October 21, 2026
Institutional holders
- BlackRock, Inc.7.93%
- VANGUARD CAPITAL MANAGEMENT LLC5.95%
- FMR LLC4.25%
- STATE STREET CORP4.09%
- WELLINGTON MANAGEMENT GROUP LLP2.35%
- Capital International Investors2.23%
- GEODE CAPITAL MANAGEMENT, LLC2.05%
- VANGUARD PORTFOLIO MANAGEMENT LLC2.04%
- JPMORGAN CHASE & CO1.75%
- Other institutions50.21%
- Rest of the register17.14%
2103 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
242.80 USD
52-week low
160.93 USD
1-year performance
16.61%
Rising
Year-to-date performance
-3.17%
Rising
Drawdown
-7.71%
Mild pullback
Position in the 52-week range
77% of range
Against the world ETF
Over 17 years, from September 2009 to August 2026, the share did not do better than the world ETF once risk is accounted for. It earned more, but shaking 2.1 times harder: for the risk taken, the ETF paid better.
10,000 € placed at the end of September 2009 are worth today
| Danaher | 198 637 € |
| World ETF | 74 620 € |
| S&P 500 | 123 025 € |
| Risk-free placement | 11 288 € |
The risk
- Shaking:the share moves 2.1 times as much as the world ETF.
- Worst fall:-46 % between August 2022 and May 2026. 10,000 € placed at the top fell to 5 394 €. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Danaher earned 3 times as much as the world ETF since 2009
Value of 10,000 euros placed at the end of September 2009, dividends reinvested, in euros
- Danaher: 198 637 €
- World ETF: 74 620 €
- S&P 500: 123 025 €
- Risk-free placement: 11 288 €
Based on past performance. This is not a recommendation.
Range: 131.27 USD - 135.91 USD (2 methods agree)
The price implies growth of 9.62% per year; the company grows at 0.65%.
Quality and profitability
10.0/10Gross margin 59.0%, net margin 15.9%, ROIC 5.4%, ROE 7.6%.
Net margin
15.89%
Exceptional
Sector 5.47%|S&P 12.97%
Gross margin
58.97%
Exceptional
Return on equity (ROE)
7.61%
Exceptional
Sector 3.01%|S&P 16.52%
Return on invested capital (ROIC)
5.43%
Exceptional
Free cash flow margin (FCF)
21.77%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.37x
Exceptional
Margin stability
4.6 pts
Steady
Revenue to net income
Growth
5.2/10Revenue up 5.5% over 1 year, 2.0% a year over 5, EPS 0.7% a year over 5.
Revenue (trailing 12 months)
25.1Md USD
Revenue growth (1y)
5.54%
Moderate
Revenue growth (3y)
-7.79%
Declining
EPS growth (1y)
59.30%
Hyper-growth
EPS CAGR (5y)
0.65%
Low
EPS revisions (3 months)
-0.01%
Revised down
Valuation
4.7/10P/E 39.8x, forward P/E 37.8x, EV/EBITDA 22.5x, PEG 60.93. The multiple sits in the 93th percentile of its own 5-year history.
P/E (TTM)
39.8x
Fair
Sector 51.0x|S&P 23.0x
Forward P/E
37.8x
Fair
EV / EBITDA
22.5x
Fair
Sector 28.4x|S&P 14.5x
PEG
60.93
Very expensive
Sector 1.76|S&P 0.86
Fair value (reverse DCF)
134.53 USD
Deeply overvalued
P/E vs its own 5-year history
among the 7% highest valuations
At its historical high
Market cap
156Md USD
Financial strength
7.2/10Cash covers 15.6% of the debt, net debt/EBITDA 2.0x.
Net debt / EBITDA
2.0x
Tight
Gearing (net debt / equity)
44.70%
Solid
Cash
4.3Md USD
Cash / market cap
2.79%
Stretched
Cash / total debt
15.61%
Tight
Interest coverage
17.6x
Very solid
Net debt
23.5Md USD
Equity
52.6Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 223.77 USD
- MM20210.96
- MM50205.50
- MM200201.80
- RSI 1468.3
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.59%
200-day average slope, 3 months
-1.04%
50-day average slope, 1 month
+4.40%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.54 % per day
Volatility change
-25.45%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 5.93 (10) | 8.51 (26) | 26 337 (24) | 8 309 (18) | 4 204 (8) |
| 2027 | 7.24 (10) | 9.30 (26) | 28 458 (24) | 9 149 (18) | 5 146 (8) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 24, 2026.
Same sub-industry: 103 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 603259 | 8.0 | 8.0 | 75.1Md USD | 22.2x | 40.2 % | 47.7 % | 29.5 % | -1.7x | 2.6 % | 56.1 % | ||
| 2 | A207940 | 7.5 | 7.9 | 46.0Md USD | 31.8x | 39.9 % | 30.2 % | 16.6 % | -0.2x | 2.3 % | -13.0 % | ||
| 3 | IQV | 6.8 | 7.0 | 44.1Md USD | 33.2x | 8.1 % | 8.8 % | 6.8 % | 4.1x | 5.0 % | 47.6 % | ||
| 4 | A | 6.5 | 6.9 | 46.6Md USD | 32.5x | 19.5 % | 8.1 % | 13.9 % | 0.9x | 2.7 % | 38.1 % | ||
| 5 | DHR | 6.5 | 6.6 | 156Md USD | 39.8x | 15.9 % | 5.5 % | 5.4 % | 2.0x | 3.5 % | 16.6 % | ||
| 6 | LONN | 6.3 | 6.1 | 46.4Md USD | Not meaningful (loss) | 16.7 % | 19.2 % | 8.7 % | 1.9x | 0.6 % | 6.1 % | ||
| 7 | TMO | 5.9 | 5.7 | 246Md USD | 35.8x | 15.0 % | 10.5 % | 7.9 % | 2.8x | 3.0 % | 45.0 % | ||
| 8 | ILMN | 4.9 | 5.1 | 38.6Md USD | 47.6x | 18.4 % | 9.8 % | 18.2 % | 0.8x | 2.4 % | 175.3 % | ||
| 9 | WAT | 4.8 | 3.8 | 41.3Md USD | 105.0x | 3.6 % | 113.3 % | 1.4 % | 0.8x | 0.9 % | 44.7 % |
